Get in Touch

Final Day of Psytech's Virtual Summit

Mindmed, Canopy Growth and Atai Scientific to Join the List of Influencers and Disrupters Speaking at Psytech's Psychedelic final day of it’s Virtual Summit
Key Takeaways
  • Final Day of 2 Day Psychedelic Virtual Summit
  • Market Disrupters Presenting
  • The virtual investor webinar is open to individualinvestors, institutional investors, advisors and analysts and the PsychedelicCommunity. The program finalizes Tuesday May 26th

Miami, Florida – May 19, 2020 - Ehave, Inc., (OTC Pink: EHVVF) (the “Company”) and its subsidiary PsyTech announced an upcoming Psychedelic Industry Webinar. The virtual investor webinar is open to individual investors, institutional investors, advisors and analysts and the Psychedelic Community. The program finalizes Tuesday May 26th   

"We invite you to join our Virtual Summit where you can learn from leading Researchers, Investors, Clinicians and Disruptors in the emerging psychedelics space. Our goal is not to focus on individual companies, but to educate on this fast-growing market," stated Ben Kaplan, CEO of Ehave, Inc.

Speakers for the PsyTech Virtual Investor Conference include:

Saul Kaye

  • Founder & CEO
  • iCAN:  Israel Cannabis

Shlomi Raz

  • Chairman/Founder
  • Eleusis

JR Rahn

  • Co-Founder/Director
  • MindMed

Hayim Raclaw

  • Managing Director
  • Psytech

Matthew Johnson, PhD.

  • Professor of Psychiatry and Behavior
  • Johns Hopkins

Click on our Webinar link for a full lineup of participants, to pre-register and run the online system check to expedite participation and receive event updates. The Psychedelic Industry Webinar and Virtual Summit is free. Registrants will be able to attend the live presentations, as well as receive links to the recorded sessions.


About Ehave, Inc.

Ehave, Inc. is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Our primary focus is on improving the standard care in therapeutics to prevent or treat brain disorders or diseases through the use of digital therapeutics, psychedelics, independently or together, with medications, devices, and other therapies to optimize patient care and health outcomes meeting privacy, HIPAA and GDPR compliance standards. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. The Ehave dashboard offers Offline Encrypted Digital Records Empowering Healthcare providers and patients and it’s a powerful machine learning and artificial intelligence platform using artificial intelligence to extract deep insights from audio, video and text to improve research with a growing set of advanced tools and applications developed by Ehave and its leading partners. This empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.

About PsyTech

PsyTech is building a vibrant community designed to explore psychedelic health and wellness, combat stigma, and accelerate innovation. PsyTech operates two matrix divisions that deliver revenue and build an equity portfolio: PsyTech Connect and PsyTech Discovery. PsyTech Connect is a premier psychedelic community platform for live and virtual conferences and an online portal for psychedelics content. PsyTech Discovery will develop ventures in psychedelic therapeutics and education. Learn more about PsyTech at

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking

statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.’s

Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website,

For Investor Relations, please contact:

Gabe Rodriguez

Phone: (623) 261-9046


For Media Inquiries, please contact:

Laura KamPhone: +972-54-806-8613


Key Takeaways
  • Final Day of 2 Day Psychedelic Virtual Summit
  • Market Disrupters Presenting
  • The virtual investor webinar is open to individualinvestors, institutional investors, advisors and analysts and the PsychedelicCommunity. The program finalizes Tuesday May 26th
Media Gallery
Gabe Rodriguez
(623) 261-9046